Dr. Hohneker joined Anokion as CEO in January 2018 with nearly three decades of drug development and leadership experience within the biotech and pharmaceutical industry.
Prior to Anokion, he was President of Research and Development at FORMA Therapeutics Inc., where he guided the company’s transition from a discovery-stage biotech to one with programs in clinical trials. Prior to FORMA, he held roles of increasing responsibility at Novartis AG, most recently as senior vice president and global head of development for immunology and dermatology, where he led the development and registration of Cosentyx® and Ilaris®. During his tenure at Novartis, Dr. Hohneker also played a key role in the development, approval, and commercialization of several products including Xolair®, Gleevec®, Tasigna®, Zometa®, Afinitor® and Exjade®. Prior to joining Novartis, he held positions of increasing responsibility at Glaxo Wellcome and its legacy company, Burroughs Wellcome.
He currently serves on the board of directors of Trishula Therapeutics, Inc., where he chairs the compensation committee. He also previously served on the board of directors of Dimension Therapeutics Inc., which was acquired by Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Torque Therapeutics, Inc. which was acquired by Cogen Immune Medicine. Dr. Hohneker received a bachelor’s degree in chemistry from Gettysburg College and a M.D. from the University of Medicine and Dentistry of New Jersey at Rutgers Medical School. He completed his internship and residency in internal medicine and his fellowship in medical oncology, all at the University of North Carolina at Chapel Hill.